Media stories about Innocoll Holdings PLC (NASDAQ:INNL) have trended positive this week, Alpha One Sentiment Analysis reports. The research group, a service of Accern, identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Innocoll Holdings PLC earned a news sentiment score of 0.33 on Alpha One’s scale. Alpha One also gave media stories about the specialty pharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
A number of brokerages recently weighed in on INNL. Zacks Investment Research cut Innocoll Holdings PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, March 1st. Stifel Nicolaus cut Innocoll Holdings PLC from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $9.00 to $2.00 in a research note on Friday, March 17th. JMP Securities upgraded Innocoll Holdings PLC to an “outperform” rating and set a $4.00 price objective for the company in a research note on Wednesday, March 29th. Finally, FBR & Co restated a “hold” rating on shares of Innocoll Holdings PLC in a research note on Thursday, April 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $3.75.
Innocoll Holdings PLC (NASDAQ:INNL) remained flat at $2.13 during midday trading on Friday. 75,013 shares of the stock were exchanged. The stock has a 50-day moving average price of $2.01 and a 200-day moving average price of $1.69. The firm’s market cap is $63.36 million. Innocoll Holdings PLC has a 12-month low of $0.53 and a 12-month high of $12.94.
Innocoll Holdings PLC Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.
Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with MarketBeat.com's FREE daily email newsletter.